Other Clinical Trial - HS2 US Liver Reader Study

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Completed

Clinical Trial Summary

The purpose of this study is to to assess the ability of 5 Gastro-Intestinal (GI) surgeons, within liver surgery, the readers, to identify pre-defined anatomical landmarks in liver images processed by HS2, and assessment of landmark distance between CT and Holographic visualization (HV).

Clinical Trial Description

This is a retrospective investigation of Computer Topographies (CTs)/ Holographic visualization based on CTs retrieved from patients with metastases in the liver from colorectal cancer. The study consists of: - Preparations at Day 0. The reader is not involved in the preparation - Using of HS2 and evaluation at Day 1-2 - Calculation at Day 3. The study will enroll eligible subject's images. ;

Study Design

Clinical Trial Details

NCT number	NCT05783284
Study type	Observational
Source	HoloCare AS
Contact
Status	Completed
Phase
Start date	March 2, 2023
Completion date	March 4, 2023

View Details